Nuwellis shares surge 12.84% intraday as Aquadex Ultrafiltration Program expands in leading Northeast children's hospital.

Nuwellis (NUWE) surged 12.84% intraday following the announcement that a leading Northeast U.S. children’s hospital initiated an Aquadex Ultrafiltration Program. The news highlighted clinician-driven adoption of Aquadex for precise fluid management in complex pediatric cardiac and cardio-renal cases, with the company emphasizing real-time hematocrit monitoring and minimal extracorporeal volume as key differentiators. Executives noted the program’s integration into care pathways at high-acuity institutions, signaling broader institutional uptake and validating Nuwellis’ pediatric growth strategy. The stock’s sharp intraday rally aligns with the news, which underscores expanding market share and clinical utility in a strategic growth segment, despite prior third-quarter revenue declines and financial challenges.